Document:

<Page>

                                                                    EXHIBIT 10.7

                     MANUFACTURING AND DEVELOPMENT AGREEMENT

     THIS AGREEMENT (this "Agreement") is effective as of February 1, 2003 (the
"Effective Date"), by and between VASO ACTIVE PHARMACEUTICALS, INC., a
corporation organized and existing under the laws of Delaware, with a registered
office situate at 99 Rosewood Drive, Suite 260, Danvers, Massachusetts 01923
("VAP") and BIOCHEMICS, INC., a corporation organized and existing under the
laws of Delaware, with a registered office situate at 99 Rosewood Drive, Suite
260, Danvers, Massachusetts 01923 ("BioChemics", together with VAP, the
"Parties" and individually each a "Party").

     WHEREAS, BioChemics develops, INTER ALIA, over-the-counter ("OTC")
pharmaceutical products that incorporate certain drug delivery technology
proprietary to BioChemics (collectively, the "OTC Products", as defined below);

     AND WHEREAS, BioChemics has certain agreements with third party contractors
to manufacture the OTC Products in accordance with specifications established by
BioChemics;

     AND WHEREAS, pursuant to a License Agreement, dated as of February 1, 2003,
by and between VAP and BioChemics (the "License Agreement"), VAP has an
exclusive, perpetual and worldwide license to commercialize, market and sell the
OTC Products;

     AND WHEREAS, pursuant to the License Agreement, BioChemics retains all
rights with respect to the manufacturing and development of the OTC Products;

     WHEREAS, VAP and BioChemics desire to formalize the terms and conditions
under which BioChemics will develop and have manufactured the OTC Products for
VAP,

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants
and conditions herein contained, VAP and BioChemics agree as follows:

ARTICLE 1 - DEFINITIONS

     1.1.   "Affiliate" shall mean (1) any corporation or business entity fifty
percent (50%) or more of the voting stock or voting equity interests of which
are owned directly or indirectly by a Party; or (2) any corporation or business
entity which directly or indirectly owns fifty percent (50%) or more of the
voting stock or voting equity interests of a Party; or (3) any corporation or
business entity directly or indirectly controlling or under control of a
corporation or business entity as described in (1) or (2).

     1.2.   "Agency" or "Agencies" shall mean the U.S. Food and Drug
Administration (hereinafter the "FDA") or any successor organization thereof and
any other government regulatory authority involved in granting approvals for the
Manufacturing or sale of over-the-counter pharmaceutical products.

     1.3.   "cGMP" shall mean all laws and regulations relating to the
Manufacturing of

<Page>

OTC Products, including, but not limited to, the Current Good Manufacturing
Practices as specified in the United States Code of Federal Regulations and any
other applicable laws, guidelines and/or regulations. In the event of conflict
Current Good Manufacturing Practices as specified in the United States Code of
Federal Regulations will prevail.

     1.4.   "Equipment" shall mean the equipment which is owned or leased by
BioChemics' Manufacturers and used in the Manufacturing of OTC Products.

     1.5.   "Manufacture / Manufacturing/ Manufactured" shall mean all
operations of BioChemics' third party manufacturers related to the
manufacturing, production, packaging, labeling, warehousing, quality control
testing, including in-process, release and stability testing when applicable,
release and shipping of OTC Products.

     1.6    "Manufacturers" shall mean collectively those third party
contractors engaged by BioChemics from time to time for the purpose of
manufacturing OTC Products for VAP.

     1.7    "OTC Products" shall have the meaning attributed to such term in the
License Agreement.

     1.8    "Purchase Order" shall mean a written form submitted by VAP to
BioChemics authorizing the purchase and delivery of OTC Products or other
services as may be specified therein, which (i) references this Agreement; (ii)
indicates the quantity and type of OTC Products that have been ordered; and
(iii) sets forth the total price to be paid for such OTC Products.

     1.9    "Purchase Price" shall have the meaning set forth in Section 5.1.

     1.10   "Second Source Supplier" shall have the meaning set forth in Section
4.2.

     1.11   "Territory" shall mean all countries of the world.

     1.12   "Facility" shall mean VAP's facility located at 99 Rosewood Drive,
Danvers, Massachusetts.

ARTICLE 2 - PURCHASE ORDERS

     Pursuant to subsequent provisions of this Agreement, BioChemics shall
develop and Manufacture and/or have Manufactured for VAP the OTC Products for
commercialization, marketing and sale in the Territory by VAP. All terms and
conditions relating to the Manufacturing and development of the OTC Products
shall be in accordance with proposals that are submitted to BioChemics by VAP
from time to time and that are agreed upon by both Parties in writing via
Purchase Orders. Purchase Orders shall be in a form agreed upon in advance by
VAP and BioChemics. In the event of that any term or condition contained in a
Purchase Order conflicts with a term or condition of this Agreement, the term or
condition contained in this Agreement shall prevail.

                                        2
<Page>

ARTICLE 3 - DEVELOPMENT AND MANUFACTURING

     3.1    BioChemics warrants, represents and covenants that it has confirmed
that each of its current Manufacturers has obtained, and BioChemics will ensure
that such current Manufacturers (and any future Manufacturers) will maintain at
all times during the period that they Manufacture OTC products for BioChemics,
all relevant and specific OTC Product approvals required by the FDA for their
respective Manufacturing facilities and that such Manufacturing facilities
conform to the applicable and current cGMP. BioChemics has also confirmed that
such Manufacturers have conformed to similar requirements of all other Agencies
having jurisdiction over the Manufacturing and development of OTC Products at
any time during the term of this Agreement.

     3.2    BioChemics certifies that all OTC Products delivered to VAP pursuant
to this Agreement will conform and be in compliance with all applicable laws and
regulations and with all regulatory requirements of all applicable Agencies
including current cGMP. In the event of conflicting laws and regulations,
compliance will be referenced by the then current 21 Code of Federal Regulation
Sections 210, 211, ET SEQ.

ARTICLE 4 - VOLUMES & SECOND SOURCE

     4.1    BioChemics shall, in accordance with the terms of this Agreement and
with any relevant and effective Purchase Order, supply VAP with OTC Products
sufficient in quantity and quality to satisfy 100% of VAP's OTC Product
requirements. Unless otherwise permitted under this Agreement, VAP will purchase
all of its OTC Products exclusively from BioChemics.

     4.2    In the event that: (i) BioChemics materially fails to meet VAP'S OTC
Product orders for a period of more than three (3) consecutive months on
accepted Purchase Orders and such Purchase Orders have been placed in accordance
with the terms of this Agreement; or (ii) BioChemics has committed an
anticipatory breach of this Agreement; or (iii) a Force Majeure has occurred
which VAP reasonably believes will affect BioChemics' ability to supply and meet
VAP's OTC Products requirements for a period of at least three (3) months; or
(iv) any of BioChemics' Manufacturers are non-compliant with the regulations
required to Manufacture OTC Products and are unable to cure such non-compliance,
VAP may qualify and engage at its discretion, such third party principal
suppliers and Manufacturers as it deems necessary to ensure uninterrupted supply
of OTC Products (each a "Second Source Supplier"); PROVIDED THAT, in any case
where VAP engages a Second Source Supplier, such Second Source Supplier shall
enter into and be bound by the terms of a confidentiality agreement, in a form
satisfactory to BioChemics, with respect to the protection and non-disclosure by
the Second Source Supplier of any confidential information relating to, among
other things, the development, Manufacturing and formulation of the OTC
Products. In no event shall the retention by VAP of a Second Source Supplier
under this Agreement constitute or affect a transfer of any of the proprietary
technology of BioChemics or VAP in relation to the OTC Products and such Second
Source Supplier shall obtain no rights whatsoever with respect to such
technology.

                                        3
<Page>

     In each such case, VAP will notify BioChemics in writing within 30-days of
VAP's decision to engage a Second Source Supplier. BioChemics shall assist VAP
in transferring the OTC Products manufacturing process to any Second Source
Supplier by providing technical assistance and documentation as necessary at
mutually agreed upon fees.

ARTICLE 5 - PRICE AND PAYMENT

     5.1    The purchase price paid by VAP to BioChemics for OTC Products shall
be based on an arm's length fee equal to BioChemics' fully loaded cost (i.e.
including all incidental costs) of the OTC Products, plus 10% (the "Purchase
Price"). VAP shall also reimburse BioChemics for the cost of preparing a precise
accounting of the costs associated with the development and manufacturing of the
OTC Products.

     5.2    Fifty percent (50%) of the Purchase Price shall be paid by VAP to
BioChemics upon the placement of each order, with the balance of the Purchase
Price payable no later than thirty (30) days after the date of BioChemics'
invoice to VAP. In the event of nonpayment of Purchase Price balances within
forty-five (45) days of the invoice date, VAP agrees to pay BioChemics a monthly
late payment charge equal to one and one-half percent (1.5%) of the unpaid
balance. Should unpaid balances extend beyond ninety (90) days without
reasonable cause after an invoice has been issued, BioChemics reserves the right
to terminate this Agreement in accordance with the terms hereof. In the
alternative, BioChemics may cease production and/or Delivery of OTC Products to
BioChemics until such non-payment has been cured.

     5.3    VAP shall be responsible for and bear all costs associated with the
design, development, quality release and regulatory approval of all labeling and
packaging materials for OTC Products supplied by BioChemics hereunder.

ARTICLE 6 - INDEMNIFICATION

     6.1.   VAP shall hold harmless and indemnify BioChemics, its employees,
officers and affiliates against any and all claims, losses, liabilities,
lawsuits, proceedings, costs and expenses, including, without limitation,
reasonable attorneys' fees, and the cost of recalls, resulting from, arising out
of or in connection with injuries and/or death resulting from, arising out of or
in connection with the commercialization, marketing or sale by VAP of the OTC
Products, including, without limitation, claims based on negligence, warranty,
strict liability or any other theory of product liability or violation of any
applicable laws or regulations, (collectively, "Claims") except to the extent
that such injuries or violations were the result of BioChemics' action, inaction
or negligence in the development, Manufacture or supply of OTC Products
according to the terms of this Agreement. If any claim shall be made against
BioChemics to which this indemnification applies, BioChemics shall immediately
inform VAP thereof of any Claim which will be brought against BioChemics and/or
VAP and in such case BioChemics shall not take any step nor conduct any legal
proceeding before consulting and obtaining VAP's written confirmation. At
BioChemics' request, VAP and/or its insurers shall assume direction and control
of the defense against such claim, including, without limitation, the settlement

                                        4
<Page>

thereof at the sole option of VAP or its insurer. BioChemics may, at its option
and expense, have its own counsel participate in any proceeding which is under
the direction and control of VAP. BioChemics shall cooperate with VAP and its
insurer in the disposition of any such matters. In addition BioChemics may at
any time relieve VAP of its responsibilities under this Section 6.1 as to any
other claim.

     6.2.   BioChemics shall hold harmless and indemnify VAP against any and all
Claims resulting from, arising out of or in connection with the action, inaction
or negligence of BioChemics or its Manufacturers in the development,
Manufacturing or supply of OTC Products to VAP according to the terms of this
Agreement except to the extent that such injuries or violations were the result
of VAP's action, inaction or negligence in the commercialization, marketing or
sale by VAP of the OTC Products in accordance with the License Agreement. If any
claims shall be made against VAP as to which this indemnification applies, VAP
shall, as soon as reasonably practicable, inform BioChemics thereof and at VAP's
request, BioChemics and/or its insurers shall assume direction and control of
the defense against such claim, including, without limitation, the settlement
thereof at the sole option of BioChemics or its insurer. VAP may, at its option
and expense, have its own counsel participate in any proceeding which is under
the direction and control of BioChemics. VAP shall cooperate with BioChemics and
its insurer in the disposition of any such matters. In addition VAP may at any
time relieve BioChemics of its responsibilities under this Section 6.2 as to any
other claim.

ARTICLE 7 - TERM; TERMINATION

     7.1.   This Agreement shall become effective on the date first stated above
and, except as otherwise provided herein, shall be in effect for an initial term
of five (5) years (the "Initial Term") and shall be automatically renewed for an
additional period of twelve (12) months so long as this Agreement has not been
terminated as permitted herein.

     7.2.   Subject at all times to Section 7.4, either Party may terminate this
Agreement for a material breach by the other Party by giving the breaching Party
written notice, specifying the breach relied on, and giving the breaching Party
three (3) months to cure such breach. If the default has not been cured at the
end of such three (3) month cure period, then, upon written notice thereof to
the breaching Party by the other, this Agreement shall terminate. Termination
for breach will have no effect on performance obligations or amounts to be paid
which have accrued up to the effective date of such termination. Notwithstanding
the foregoing, BioChemics shall not be considered to have committed a material
breach for the purposes of this Section 7.2 if, as a result of a decision,
ruling, order or change of policy or regulation of any Agency, BioChemics
becomes unable to Manufacture any OTC Product or is required to change the
formulation of such OTC Product. In such case, VAP shall be permitted to retain
the services of a Second Source Supplier in accordance with Section 4.2 hereof,
but shall not be permitted to terminate this Agreement.

     7.3.   In event of termination, transition will be conducted in such a
manner as to not cause inconvenience to either Party. Should termination be
initiated by BioChemics, BioChemics shall notify VAP in writing of its desire to
so terminate. Termination by BioChemics for any

                                        5
<Page>

reason, except for non-payment, shall not be effective until VAP has located and
arranged for continuation of the Manufacturing of OTC Products with another
supplier on terms commercially reasonable to VAP; PROVIDED HOWEVER, that VAP
shall have no longer than 2 years from the date of the notice of termination
from BioChemics to make such arrangements. During any such interim period,
BioChemics shall continue to Manufacture OTC Products for VAP in accordance with
this Agreement. In the event of notice of termination by BioChemics for any
reason, BioChemics shall perform such functions reasonably necessary or required
in connection with the orderly wind-down of any active order with VAP as
required by the terms of this Agreement or federal, state, or local laws or
regulations, including applicable Agency regulations.

ARTICLE 8 - NOTICES

     Any and all notices or other communications required or permitted under
this Agreement must be in written form and be deemed to have been given upon
receipt of telefax to the notified Party (followed by hard copy of documents)
addressed to the Party to be notified as listed in the beginning of this
Agreement, or to such other address as either Party shall have heretofore
specified in a notice to the other in the manner herein provided.

ARTICLE 9 - WAIVER

     No failure on the part of either Party to exercise, and no delay in
exercising, and no course of dealing with respect to, any right, power or
privilege under this Agreement shall operate as a waiver thereof, nor shall any
single or partial exercise of any right, power or privilege under this Agreement
preclude any other or further exercise thereof or the exercise of any other
right, power or privilege.

ARTICLE 10 - ASSIGNMENT OF AGREEMENT

     Neither this Agreement, nor any rights or obligations hereunder, may be
assigned by either Party without the prior written consent of the other Party,
which consent shall not be unreasonably withheld; provided that VAP may assign
its rights and obligations hereunder to an Affiliate or a purchaser of all or
substantially all of the stock or assets of VAP. Any subsequent assignee,
purchaser, or transferee shall be bound by the terms of this Agreement.

ARTICLE 11 - GOVERNING LAW

     All questions concerning the construction, validity, and interpretation of
this Agreement and the performance of the obligations imposed by this Agreement
shall be governed by the internal law, not the law of conflicts, of the
Commonwealth of Massachusetts.

ARTICLE 12 - ENTIRE AGREEMENT

     This Agreement, together with the Attachments identified herein that shall
form part of this Agreement, constitutes the entire understanding between the
parties and is intended as a final

                                        6
<Page>

expression of their agreement and as a complete statement of terms and
conditions thereof, and shall not be amended except in writing signed by an
authorized representative of each Party and specifically referring to this
Agreement. If there is any inconsistency between this document and any other
writings, which are referred to or are incorporated herein, or any purchase
orders, invoices, or other documents relating to the development and
Manufacturing of the OTC Products, the terms and conditions of this document
shall take precedence. This Agreement supersedes any previous agreements or
arrangements between the parties and any customary practice of the parties at
variance with the terms hereof.

ARTICLE 13 - SEVERABILITY

     In the event any provision of this Agreement is held to be invalid or
unenforceable, the valid or enforceable portion thereof and the remaining
provisions of this Agreement will remain in full force and effect.

ARTICLE 14 - INDEPENDENT CONTRACTOR

     Neither Party shall have the right to control the activities of the other
in the performance of this Agreement and each shall perform as an independent
contractor, and nothing herein shall be construed to be inconsistent with that
relationship or status. Under no circumstances shall the employees or agents of
one Party be considered employees or agents of the other. This Agreement shall
not constitute, create, or in any way be interpreted as a joint venture,
partnership, or formal business organization of any kind.

ARTICLE 15 - AMENDMENTS

     No provision of this Agreement or the Attachments attached hereto may be
modified or supplemented, except by an instrument in writing signed by both
BioChemics and VAP.

ARTICLE 16 - HEADINGS

     The Article headings appearing herein are included only for the convenience
of reference and are not intended to affect the interpretation of any provision
of this Agreement.

ARTICLE 17 - RECALL

     In the event (a) any governmental authority of the United States issues a
request, directive, or order that an OTC Product be recalled, or (b) a court of
competent jurisdiction orders such a recall, or (c) the parties reasonably
determine after consultation with each other that an OTC Product should be
recalled (a "Recall"), the parties shall take all appropriate corrective action.
VAP shall also retain the right to conduct an OTC Product Recall for safety
reasons VAP deems significant. In the event that an OTC Product is recalled or
that VAP is required to disseminate information regarding OTC Products covered
by this Agreement, VAP shall so notify BioChemics and, not later than may be
required to permit VAP to meet such obligations, BioChemics shall provide VAP
with such assistance in connection with such recall as may

                                        7
<Page>

reasonably be requested by VAP. The Party responsible for any Recall will be
financially responsible for the costs of such Recall; provided that in no case
shall such Party shall be responsible for any loss of profit, sales or
consequential damages suffered by the other Party where such losses are directly
associated with, or attributable to, such Recall.

ARTICLE 18 - COUNTERPARTS

     This Agreement may be signed by the Parties executed in one or more
counterparts as may be deemed necessary, each of which so signed shall be deemed
to be an original, and all such counterparts together shall constitute one and
the same instrument. Delivery of an executed signature page to this Agreement by
facsimile transmission shall be as effective as delivery of a manually signed
counterpart of this Agreement.

                      [THE SIGNATURE PAGE IS THE NEXT PAGE]

                                        8
<Page>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement by
their duly authorized representatives as of the dates set forth below:

For:        VASO ACTIVE PHARMACEUTICALS, INC.

Name:       John J. Masiz
Title:      President

Signature:
          -------------------------------------

Date:
      ------------------------------

For:        BIOCHEMICS, INC.

Name: John J. Masiz
Title: President

Signature:
          -------------------------------------

Date:
      ------------------------------

                                       9QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.50    
    

LETTER AGREEMENT  

June 24,
2003 

Special
Devices, Incorporated

14370 White Sage Road

Moorpark, CA 93021 

Ladies
and Gentlemen: 

        This
letter agreement is entered into by and between Special Devices, Incorporated, a Delaware corporation (the "Company"), and Wells Fargo Foothill, Inc. (the "Lender") (this
"Letter Agreement"). Reference is made to that certain Loan and Security Agreement dated as of June 27, 2001, between the Company and Lender (as amended, the "Loan Agreement"). Capitalized
terms used but not otherwise defined in this Letter Agreement shall have the meanings ascribed to them in the Loan Agreement. The term "Loan Documents" as defined in the Loan Agreement is hereby
amended and supplemented to include this Letter Agreement. 

        The
Company may wish, from time to time, to present for payment to Wells Fargo Bank ("Wells Fargo") certain checks or drafts made payable to the Company that are denominated in a foreign
currency (collectively, the "Foreign Drafts"). In addition to seeking payment on the Foreign Drafts, the Company may request that Wells Fargo convert the proceeds of the Foreign Drafts into United
States Dollars (such conversions being referred to herein as the "Currency Conversions"). 

        Wells
Fargo may agree, in Well Fargo's discretion, from time to time to assist with the payment or collection of the Foreign Drafts and/or the Currency Conversions, so long as Lender
agrees to reimburse and/or indemnify Wells Fargo (i) in the event that any Foreign Draft is not paid or honored for any reason, and (ii) for any other cost, expense, loss, claim, action,
or damages arising from or incurred in connection with such Foreign Drafts or the Currency Conversions (collectively, "Wells Fargo Claims"). 

        In
order to induce Lender to agree to reimburse and indemnify Wells Fargo for any and all Wells Fargo Claims, the Company agrees to reimburse and indemnify Lender, on demand, for any
cost, expense, loss, claim, action, or damages arising from or incurred by Lender in connection with the Wells Fargo Claims, whether now existing or hereafter arising (the "Lender Claims"). Such
reimbursement and indemnification obligations of the Company shall be deemed to be "Obligations" under the Loan Agreement. 

        Any
Obligation of the Company to make payments to Lender arising out of Lender Claims shall be irrevocable, without any qualification or exception whatsoever, and shall be made without
set-off or defense under all circumstances, including, without limitation, any of the following: (i) any lack of validity or enforceability of the Loan Agreement, this Letter
Agreement, and any other Loan Document, (ii) the existence of any claim, setoff, defense or other right that the Company or Lender may have at any time against Wells Fargo or any other Person
in connection with the Wells Fargo Claims, (iii) any certificate, notice, document, representation or any statement presented to or by, or asserted by, Wells Fargo proving to be forged,
fraudulent, invalid, or insufficient in any respect, and (iv) any payment of the Wells Fargo Claims by Lender based on any error, negligence or mistake, whether omission or commission, except
for any gross negligence or willful misconduct on the part of Lender. 

        This
Letter Agreement may be executed in counterparts, each of which shall constitute an original, but all of which taken together shall constitute one and the same instrument. The terms
and conditions of the Loan Agreement are hereby incorporated by reference into this Letter Agreement. 

        This
Letter Agreement shall become effective upon Borrower's returning a executed copy of this Letter Agreement to Lender 

        Please
indicate your agreement by signing as indicated below. 

	Very truly yours,	 	 
	 	 	 
	WELLS FARGO FOOTHILL, INC.	 	 
	 	 	 
	 	 	 
	/s/ JOHN NOCITA
	 	 

AGREED AND ACKNOWLEDGED:  

SPECIAL
DEVICES, INCORPORATED 

	By:	 	/s/ JAMES E. REEDER
	 	 
	Name:	 	JAMES E. REEDER
	 	 
	Title:	 	VICE PRESIDENT FINANCE
	 	 
	Date:	 	JUNE 25, 2003
	 	 

QuickLinks

Exhibit 10.50

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]